romilkimab (SAR156597) - Sanofi
SAR156597: Data from P2a trial (NCT02921971) for scleroderma in 2019 (Sanofi) - Apr 27, 2019 - Q1 2019 Results 
P2a data
https://www.sanofi.com/-/media/Project/One-Sanofi-Web/Websites/Global/Sanofi-COM/Home/en/investors/docs/Q-R/Q1_2019_rnd_appendix.pdf?la=en&hash=2A03A80E8CC0C45BBD821F739572D571E9C78154
 
Apr 27, 2019
 
 
37031a90-33a8-4280-a933-2325249a2666.jpg